As a prominent inflammatory effector of cyclooxygenase-2 (COX-2), prostaglandin E2 (PGE 2 ) mediates brain inflammation and injury in many chronic central nervous system (CNS) conditions including seizures and epilepsy, largely through its receptor subtype EP2. However, EP2 receptor activation might also be neuroprotective in models of excitotoxicity and ischemia. These seemingly incongruent observations expose the delicacy of immune and inflammatory signaling in the brain; thus the therapeutic window for quelling neuroinflammation might vary with injury type and target molecule. Here, we identify a therapeutic window for EP2 antagonism to reduce delayed mortality and functional morbidity after status epilepticus (SE) in mice. Importantly, treatment must be delayed relative to SE onset to be effective, a finding that could be explained by the time-course of COX-2 induction after SE and compound pharmacokinetics. A large number of inflammatory mediators were upregulated in hippocampus after SE with COX-2 and IL-1β temporally leading many others. Thus, EP2 antagonism represents a novel anti-inflammatory strategy to treat SE with a tightly-regulated therapeutic window.
Introduction
Though the central nervous system (CNS) was historically considered immune-privileged, inflammation within the brain, also known as neuroinflammation, is now emerging as a salient feature of many chronic neurological conditions that might contribute to the pathogenesis of these diseases (Aronica and Crino, 2011; Lucas et al., 2006; Varvel et al., 2015; Wee Yong, 2010) . Resembling its extraneural counterpart, neuroinflammation involves a wide range of inflammatory molecules that mediate both pro-and anti-inflammatory events. Among these, cyclooxygenase (COX) is widely recognized for its pivotal role in initiation then prolongation of inflammatory responses via its prostanoid products, consisting of prostaglandin E 2 (PGE 2 ), PGD 2 , PGF 2α , prostacyclin I 2 , and thromboxane A 2 . COX-2 is the isozyme primarily responsible for prostanoid production under acute or chronic inflammatory conditions, whereas COX-1 is constitutively expressed in various tissues maintaining normal homeostatic functions of prostanoids (Hla and Neilson, 1992; Jiang and Dingledine, 2013a) . COX-2 is rapidly induced in principal brain neurons in response to injury or excessive neuronal activity, and its overexpression is often associated with neurotoxicity and tissue injury in acute conditions including seizures (Kelley et al., 1999; Serrano et al., 2011; Takemiya et al., 2006) and ischemia (Iadecola et al., 2001; Kawano et al., 2006) , as well as in chronic inflammatory diseases such as Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), and Creutzfeldt-Jakob disease (Minghetti, 2004) .
Although the COX-2 downstream signaling pathways involved in inflammation and tissue injury have not been fully identified, PGE 2 signaling through its EP2 receptor appears to play a major role in peripheral inflammation and pain observed in chronic inflammatory diseases such as rheumatoid arthritis, skin and vascular inflammation, and inflammatory hyperalgesia (Jiang and Dingledine, 2013a) . In the brain, PGE 2 is a predominant COX-2 product and the EP2 receptor is also widely expressed. Extensive studies in the past decade reveal that PGE 2 signaling via EP2 mediates pro-inflammatory effects in models of innate immunity (Ganesh et al., 2013; Johansson et al., 2013; Montine et al., 2002) , AD (Johansson et al., 2015; Liang et al., 2005) , ALS (Liang et al., 2008) and more recently status epilepticus (SE) (Jiang et al., 2012 (Jiang et al., , 2013 , and slows the clearance of toxic substances such as amyloid beta (Aβ) peptides (Keene et al., 2010; Shie et al., 2005a Shie et al., , 2005b and Neurobiology of Disease 76 (2015) 126-136 
